Theriva Biologics, Inc. (TOVX) is a publicly traded Healthcare sector company. As of May 21, 2026, TOVX trades at $0.30 with a market cap of $13.54M and a P/E ratio of -0.14. TOVX moved +11.05% today. Year to date, TOVX is +24.48%; over the trailing twelve months it is -31.22%. Its 52-week range spans $0.16 to $2.64. Analyst consensus is buy with an average price target of $2.50. Rallies surfaces TOVX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Theriva Biologics Posts $2M Q1 Loss, $14.4M Cash and FDA Aligns on Phase 3: Theriva Biologics lost $2.0M in Q1 (5 cents per share) on $300k revenue and reduced R&D expenses by 88% to $355k. The company holds $14.4M cash, secured FDA alignment on its pivotal Phase 3 trial for VCN-01 in metastatic PDAC and plans a Phase 3 dosing study in Spain.
| Metric | Value |
|---|---|
| Price | $0.30 |
| Market Cap | $13.54M |
| P/E Ratio | -0.14 |
| EPS | $-2.08 |
| Dividend Yield | 0.05% |
| 52-Week High | $2.64 |
| 52-Week Low | $0.16 |
| Volume | 158.50K |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-23.74M |
| Gross Margin | 0.00% |
2 analysts cover TOVX: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $2.50.